Guidance and quality standards Awaiting development
Showing 21 to 25 of 25
Title | Type |
---|---|
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation TS ID 11841 | Technology appraisal guidance |
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122] | Technology appraisal guidance |
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer TS ID 10693 | Technology appraisal guidance |
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934] | Technology appraisal guidance |
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TS ID 11950 | Technology appraisal guidance |